AstraZeneca PLC
A1ZN34.SA
| Exchange: | SA |
| Currency | Brazilian real |
| Fiscal Year End: | December |
| Sector: | Healthcare |
| Industry: | Drug Manufacturers - General |
| Gic Sector: | Health Care |
| Gic Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| Gic Industry: | Pharmaceuticals |
| Gic Sub Industry: | Pharmaceuticals |
| Home Category: | BDR |
| Is Delisted: | False |
| Description: | Astra Zeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, Flu Mist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; Benevolent AI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to Astra Zeneca PLC in April 1999. Astra Zeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. |
| Address: | 1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA |
| Website: | https://www.astrazeneca.com |
| Full Time Employees: | 89900 |
| Updated On: | 2024-11-02 |
Highlights
| Market Capitalization: | 1294989656064 |
| Market Capitalization Mln: | 1294989.65 |
| EBITDA: | 16972999680 |
| PE Ratio: | 34.97 |
| PEG Ratio: | 0.80 |
| Book Value: | 25.49 |
| Dividend Share: | 2.97 |
| Dividend Yield: | 0.01 |
| Earnings Share: | 1.99 |
| Most Recent Quarter: | 2024-06-30 |
| Profit Margin: | 0.13 |
| Operating Margin TTM: | 0.22 |
| Return On Assets TTM: | 0.07 |
| Return On Equity TTM: | 0.16 |
| Revenue TTM: | 49132998656 |
| Revenue Per Share TTM: | 2.63 |
| Quarterly Revenue Growth YOY: | 0.13 |
| Gross Profit TTM: | 35732000000 |
| Diluted Eps TTM: | 1.99 |
Valuation
| Trailing PE: | 34.97 |
| Forward PE: | 15.40 |
| Price Sales TTM: | 26.35 |
| Price Book MRQ: | 5.65 |
| Enterprise Value: | 1429733148320 |
| Enterprise Value Revenue: | 5.02 |
| Enterprise Value Ebitda: | 17.52 |
Shares
| Shares Outstanding: | 18603499520 |
| Shares Float: | 1544528500 |
Technicals
| Beta: | 0.16 |
| 52 Week High: | 82.8 |
| 52 Week Low: | 49.76 |
| 50 Day MA: | 73.79 |
| 200 Day MA: | 66.78 |
Splits & Dividends
| Forward Annual Dividend Rate: | 1.26 |
| Forward Annual Dividend Yield: | 0.01 |
| Payout Ratio: | 0.69 |
| Ex Dividend Date: | 2024-08-08 |